ClinicalTrials.gg
WithdrawnNCT02760615Updated Oct 27, 2020

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

A Phase 4 interventional study of Caffeine and Losartan in Colitis, Ulcerative and Crohn Disease, sponsored by Takeda. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-27.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Why this study was withdrawn
No enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
35th of 38
0 · median 110
Started
2016
with 2 others
Phase 4
15 of 38
2 open now
Registered
12th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 35th largest by enrollment, is one of 3 that started in 2016, is one of 15 in phase 4, and was the 12th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate in a step-wise approach the disease drug-drug interaction (DDI) potential for vedolizumab to indirectly affect the exposure of cytochrome P-450 (CYP) substrate drugs by modulating pro-inflammatory cytokines in participants with ulcerative colitis (UC) or Crohn's disease (CD) who are treated with vedolizumab.

Read the detailed description

The drug being tested in this study is called vedolizumab, which is being tested to assess the possibility of drug-drug interactions when administered with other medications. The study will comprise of 2 parallel parts: Part 1 and Part 2.

Part 1 will enroll approximately 40 participants: 20 healthy participants and 20 participants with UC or CD who are not currently being treated with vedolizumab. All participants will receive the following medications:

  • Caffeine 100 mg
  • Losartan 50 mg
  • Omeprazole 20 mg
  • Dextromethorphan 30 mg
  • Midazolam 2 mg

Part 2 will enroll approximately 20 participants on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for the treatment of UC or CD. Participants will receive the same medications and dosages as in Part 1 in addition to their scheduled vedolizumab 300 mg IV.

This multi-center trial will be conducted in the United States. For Part 1 and Part 2, participants will arrive at study unit for check-in (Day -1) and will return to the study unit for dosing and PK assessment on Day 1 and study exit on Day 2 or will be kept from Check-in through at least 24 hours after dosing for safety and PK assessments before discharge. The total confinement period (optional) will be up to 3 days for both the parts. The overall time to participate for each participant in Part 1 will be approximately 6 weeks and for Part 2, it will be approximately 12 weeks.

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.
  3. Is a cytochrome P-450 (CYP)2C9, CYP2C19, and CYP2D6 extensive metabolizer, based on genotyping of pharmacogenomic (PGx) deoxyribonucleic acid (DNA) analysis.
  4. Is a male or female aged 18 to 55 years, inclusive, at Screening.
  5. Weighs at least 50 kilogram (kg) and has a (BMI) of 18.0 to 30 kilogram per square meter (kg/m\^2), inclusive, at Screening and Check-in (Day -1).
  6. The healthy control participants in Part 1 of this study will be matched at Day-1 with the UC or CD participants in Group 1 or 3 (whichever enrolls faster) on the basis of age (+/-10 years), gender and weight (+/-30 [percent] %).
  7. Participants in Part 2 and Group 1 will be matched on Day-1 on the basis of the inflammatory bowel disease (IBD) diagnosis (UC or CD), age (+/-10 years), gender and weight (+/-30%).

    For Part 1 Participants:

  8. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study.
  9. All female participants who are of childbearing potential and who are sexually active, agree to routinely use adequate contraception from signing of informed consent throughout the duration of the study. NOTE: Female participants NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [at least 2 years post-operation]) or who are (example, defined as at least 1 year since last regular menses with an follicle stimulated hormone [FSH] greater than [>] 40 international units per liter [IU/L] or at least 5 years since last regular menses, confirmed before any study medication is implemented).

    For Part 1 Only Participants with UC or CD

  10. Has a diagnosis of UC or CD established at least 6 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report.
  11. Prior to entering the study, participants with UC must have had an endoscopy during screening to confirm active disease, with Mayo score of 6 to 12 and an endoscopic subscore greater than or equal to (>=)2. Participants with CD must have a Crohn's Disease Activity Index (CDAI) score of 220 to 450 to confirm moderate to severe disease on entry (that is, Day-1).
  12. Participant may be receiving a therapeutic dose of the following drugs for treatment of their underlying disease:

    • Oral or topical 5-aminosalicylic acid (5-ASA) compounds provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
    • Probiotics (example, Culturelle, Saccharomyces boulardii) provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
    • Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
    • Azathioprine or 6-mercaptopurine, provided that the dose has been stable for the 8 weeks immediately prior to enrollment.
    • Methotrexate provided that the dose has been stable for the 8 weeks immediately prior to randomization.
    • Oral therapy (prednisone at a stable dose less than or equal to [\<=] 30 milligram per day [mg/day], or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment, if corticosteroids have been initiated, or for the 2 weeks immediately prior to the enrollment, if corticosteroids are being tapered.
  13. C-reactive protein (CRP) >=5 milligram per liter (mg/L) during screening period in participants with CD.

    For Part 1 Healthy Participants Only:

  14. The participant, in opinion of the investigator, is in healthy condition as determined by a prestudy physical examination, medical history, vital signs, (ECG), and the results of blood biochemistry, hematology, serology, and urinalysis tests.

    For Part 2 Participants with Active UC and CD:

  15. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 57 days after last dose.
  16. All female participants who are of childbearing potential and who are sexually active with a nonsterilized male partner, agree to routinely use adequate contraception from Screening until 57 days after receiving the last dose of study medication. NOTE: Female participants NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [at least 2 years post-operation]) or who are postmenopausal (example, defined as at least 1 year since last regular menses with an FSH >40 IU/L or at least 5 years since last regular menses, confirmed before any study medication is implemented.
  17. Has a diagnosis of UC or CD established at least 6 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report.
  18. Is on established vedolizumab intravenous (IV) for treatment of UC or CD and is in clinical remission as assessed within 7 days of dosing defined for UC; A complete Mayo score of \<=2 points and no individual subscore >1 point. For CD; CDAI of \<=150 points.
  19. Participant may be receiving a therapeutic dose of the following drugs for treatment of their underlying disease:

    • Oral or topical ASA compounds provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
    • Probiotics (example, Culturelle, S. boulardii) provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
    • Antidiarrheals (eg, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
    • Azathioprine or 6-mercaptopurine, provided that the dose has been stable for the 8 weeks immediately prior to enrollment.
    • Methotrexate provided that the dose has been stable for the 8 weeks immediately prior to randomization.
    • Oral corticosteroid therapy (prednisone at a stable dose \<30 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have been initiated or for the 2 weeks immediately prior to the enrollment if corticosteroids are being tapered.

Exclusion criteria

Exclusion Criteria:

For both Part 1 and Part 2:

  1. Has a known to any of the drugs or components in the Injection (Inje) Cocktail.
  2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example, spouse, parent, child, sibling) or may consent under duress.
  3. Within 30 days prior to enrollment, participants with UC or CD have received any treatment of underlying disease other than those specifically listed in the protocol for the Treatment of UC or CD.
  4. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 57 days after participating in this study; or intending to donate ova during such time period.
  5. If male, the participant intends to donate sperm during the course of this study or for 57 days thereafter.
  6. Has received rituximab or natalizumab treatment or other integrin inhibitors.
  7. Has taken any excluded medication, supplements, or food products listed in the protocol.
  8. Has evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.
  9. Has had extensive colonic resection, subtotal or total colectomy.
  10. Has had ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  11. Has evidence of or has had treatment for Clostridium difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment.
  12. Has a history or evidence of adenomatous colonic polyps that have not been removed.
  13. Has a history or evidence of colonic mucosal dysplasia.
  14. Has chronic virus (HBV) or virus (HCV) infection.
  15. Has any identified congenital or acquired immunodeficiency (example, common variable immunodeficiency, [HIV] infection, organ transplantation).
  16. Has received any within 30 days prior to study drug administration except for the influenza vaccine.
  17. Has infection (example, pneumonia, pyelonephritis) within 30 days prior to enrollment.
  18. Has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  19. Has had any surgical procedure requiring general anesthesia within 30 days prior to enrollment or is planning to undergo major surgery during the study period.
  20. Has any history of , except for the following: (a) adequately treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to enrollment; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to enrollment. Participants with remote history of malignancy (example, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.
  21. Has a current or recent history (within 1 year prior to enrollment) of alcohol dependence or illicit drug use.
  22. Has active psychiatric problems that, in the investigator's opinion, may interfere with compliance with the study procedures.
  23. Is unable to attend all the study visits or comply with study procedures.

    For Part 1 Participants With UC or CD:

  24. Has received any or approved biologic or biosimilar agent in the last 6 months prior to Screening.
  25. Participant currently requires or is anticipated to require surgical intervention for UC or CD during the study.

    For Part 1 Healthy Participants Only:

  26. Has laboratory abnormalities considered to be clinically significant by the investigator during the Screening Period, for example the following:

    • level less than (\<) 10 gram per decilitre (g/dL).
    • White blood cell (WBC) count \<3*10\^9 per liter (/L).
    • Lymphocyte count \<0.5*10\^9/L.
    • count \<100*10\^9/L or >1200*10\^9/L.
    • (ALT) or aspartate aminotransferase (AST) > (ULN).
    • Alkaline phosphatase >ULN.
    • Serum creatinine >1.5*ULN.

    For Part 1 Participants with UC or CD and Part 2 Participants:

  27. Has any of the following laboratory abnormalities considered to be clinically significant by the investigator during the Screening Period:

    • Hemoglobin level \<8 g/dL.
    • WBC count \<3*10\^9/L.
    • Lymphocyte count \<0.5 x 10\^9/L.
    • Platelet count \<100*10\^9/L or >1200*10\^9/L.
    • ALT or AST >3*ULN.
    • Alkaline phosphatase >3*ULN.
    • Serum creatinine >2*ULN.

    For Part 2 only:

  28. Has received any investigational or approved biologic or biosimilar agents other than vedolizumab in the last 6 months prior to Screening.
  29. The subject has active or latent tuberculosis (TB), this may involve documentation of the participant's TB status prior to commencing vedolizumab with the participant's own treating physician.
  30. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  31. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at screening and prior to dosing on Day 1.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Other
    Part 1: UC and CD Participants

    Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.

    Drug: Caffeine · Drug: Losartan · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Midazolam · Drug: Vedolizumab

  • Other
    Part 1: Healthy Participants

    Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.

    Drug: Caffeine · Drug: Losartan · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Midazolam · Drug: Vedolizumab

  • Experimental
    Part 2: Vedolizumab

    Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2\*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.

    Drug: Caffeine · Drug: Losartan · Drug: Omeprazole · Drug: Dextromethorphan · Drug: Midazolam · Drug: Vedolizumab

Interventions

  • DrugCaffeine

    Caffeine tablets

  • Losartan tablets

    Also known as: Cozaar

  • DrugOmeprazole

    Omeprazole capsules

    Also known as: Prilosec

  • DrugDextromethorphan

    Dextromethorphan capsules

    Also known as: Delsym

  • DrugMidazolam

    Midazolam syrup

    Also known as: Versed

  • Vedolizumab solution for IV infusion

06

What researchers measure

Primary outcomes

  1. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Caffeine

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  2. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Losartan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  3. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Omeprazole

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  4. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dextromethorphan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  5. AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Midazolam

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  6. AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Caffeine

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  7. AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Losartan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  8. AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Omeprazole

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  9. AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Dextromethorphan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  10. AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Midazolam

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  11. Cmax: Maximum Observed Plasma Concentration for Caffeine

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  12. Cmax: Maximum Observed Plasma Concentration for Losartan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  13. Cmax: Maximum Observed Plasma Concentration for Omeprazole

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  14. Cmax: Maximum Observed Plasma Concentration for Dextromethorphan

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

  15. Cmax: Maximum Observed Plasma Concentration for Midazolam

    Time frame: Predose and at multiple time points (up to 24 hours) postdose

07

Study locations

2 sites
  • WCCT
    Cypress, California 90630, United States
  • QPS MRA
    Miami, Florida 33143, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2016; primary completion for Aug 2020, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2016
First posted
May 3, 2016
StartEst.
Nov 1, 2016
Primary completionEst.
Aug 1, 2020
CompletionEst.
Aug 1, 2020
Last update
Oct 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02760615
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 3, 2016
Start date
Nov 1, 2016 (estimated)
Primary completion
Aug 1, 2020 (estimated)
Completion
Aug 1, 2020 (estimated)
Last update
Oct 27, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion